Haematology

Browse

Recent Submissions

  • Publication
    A double-centre retrospective study into rates of postpartum haemorrhage in women on low molecular weight heparin
    (Wiley, 2015-04-19) Browne, R.; Arbuthnot, C.; Nicolle, C. S.; Erb, S. J.; Farrall, L.; Borg, A.; University Hospitals Coventry and Warwickshire NHS Trust; South Warwickshire University NHS Foundation Trust; Haematology; Medical and Dental; Arbuthnot, C.; Borg, A.
    Haemostasis and Thrombosis poster abstract 90 of the 55th Annual Scientific Meeting of the British Society for Haematology, 20-22 April 2015, Edinburgh, UK.
  • Publication
    Acquired isodisomy on chromosome 13 at diagnosis results in impaired overall survival in patients with FLT3-ITD mutant acute myeloid leukaemia
    (Springer Nature, 2015-06-19) Loke, J. C. T.; Akiki, S.; Borrow, J.; Ewing, J.; Bokhari, S. W.; Chandra, D.; Arrazi, J.; Hazlewood, P.; Arthur, K.; Walsh, J.; Membwange, Y.; Wandroo, F. A.; Watts, A.; Borg, A.; Brock, K.; Ferguson, P.; Craddock, C.; Griffiths, M.; Raghavan, M.; University Hospitals Birmingham NHS Foundation Trust; West Midlands Regional Genetics Laboratory, Birmingham; University Hospitals Coventry and Warwickshire NHS Trust; University Hospital of North Staffordshire; Worcestershire Royal Hospital; New Cross Hospital, Wolverhampton; Sandwell and West Birmingham Hospitals NHS Trust; The Dudley Group NHS Foundation Trust; South Warwickshire University NHS Foundation Trust; University of Birmingham; Haematology; Medical and Dental; Borg, A.; Arrazi, Julie; Ferguson, Paul; Craddock, Charles; Raghavan, Manoj; Ewing, Joanne
    Internal tandem duplication (ITD) mutations in the FLT3 gene on chromosome 13 occur in 25% of patients with acute myeloid leukaemia (AML) and result in impaired overall survival (OS). Patients with a high allelic ratio (AR) of ITD mutant to wild-type FLT3 in genomic DNA have an even poorer prognosis. AR may be a predictor of response to FLT3 inhibitors and may also interact with other mutations in influencing disease risk. AR may be dependent on a number of factors including loss of the wild-type allele. Acquired isodisomy (AID) results in loss of the wild-type allele, through duplication of the mutant allele with segmental loss of the wild-type allele. Although studies have shown the importance of AID at chromosome 13 (AID13) at relapse, the impact of AID13 at diagnosis is unclear. The study reported in this Letter to the Editor aimed to identify the relationship between AID13 and FLT3-ITD AR and investigated the outcomes of patients with AID13.
  • Publication
    Steroid refractory autoimmune haemolytic anaemia secondary to sarcoidosis successfully treated with rituximab and mycophenolate mofetil
    (Wiley, 2016-08-02) Green, Sarah; Partridge, Erica; Idedevbo, Edore; Borg, Anton; South Warwickshire University NHS Foundation Trust; Haematology; Medical and Dental; Green, Sarah; Partridge, Erica; Idedevbo, Edore; Borg, Anton
    Autoimmune haemolytic anaemia is not a well-recognised complication of sarcoidosis. We describe the case of a 30-year-old female who presented with acute warm haemolytic anaemia and widespread lymphadenopathy. Sarcoidosis was diagnosed on lymph node biopsy and further investigation. The haemolytic anaemia responded only to a high dose of steroids. Evidence regarding treatment of steroid refractory autoimmune haemolysis secondary to sarcoidosis is lacking. Based on the emergent evidence that both disorders share common immunopathogenic mechanisms involving Th1 and Th17 lymphocytes, our patient was given rituximab and mycophenolate mofetil to successfully suppress the haemolysis and sarcoid activity.
  • Publication
    Efficacy and safety of RCEOP chemotherapy in patients with diffuse large cell lymphoma (DLCL) not fit for anthracyclines are comparable to RCHOP
    (Wiley, 2016-04-12) Abdulwahid, D.; Arbuthnot, C.; Paneesha, S.; Jobanputra, S.; Borg, A.; University Hospitals Coventry and Warwickshire NHS Trust; South Warwickshire University NHS Foundation Trust; Heart of England Foundation NHS Trust, Birmingham; Haematology; Medical and Dental; Arbuthnot, C.; Borg, A.
    Poster abstract 198 in the section 'Lymphoid Malignancy – Clinical' of the XXXVI World Congress of the International Society of Hematology, hosted by the British Society for Haematology, 18–21 April 2016, Glasgow, UK.
  • Publication
    Haemolytic uraemic syndrome associated with docetaxel in breast cancer
    (International Gynecologic Cancer Society, 2016-10) Allos, B.; Dunn, V.; Walji, N.; Short, A.; Borg, A.; University Hospitals Coventry and Warwickshire NHS Trust; South Warwickshire University NHS Foundation Trust; Haematology; Medical and Dental; Borg, A.
    Conference abstract IGCS-0299 of the 16th Biennial Meeting of the International Gynecologic Cancer Society, Lisbon, Portugal, October 28-31, 2016.
  • Publication
    Immune reconstitution at 12 months can predict superior overall survival in reduced intensity alemtuzumab based conditioning transplant recipients for high risk MDS and AML ; a single centre experience
    (Springer Nature, 2016-03-21) Kanellopoulos, A.; Saeed, M.; Kaparou, M.; Eden, D.; Khawaja, J.; Cain, L.; Qureshi, I.; Xenou, E.; Lee, S.; Randall, K.; Arbuthnot, C.; Borg, A.; Holder, K.; Bratby, L.; Kishore, B.; Lovell, R.; Paneesha, S.; Nikolousis, E.; Heart of England NHS Trust; New Cross Hospital, Wolverhampton; South Warwickshire University NHS Foundation Trust; Haematology; Medical and Dental; Randall, K.; Arbuthnot, C.
    Physicians Poster Sessions abstract P245 of the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, Valencia, Spain, 3–6 April 2016.
  • Publication
    Full donor whole blood chimerism can predict superior progression free survival in reduced intensity alemtuzumab based conditioning transplant recipients for high risk MDS and AML ; a single centre experience
    (Springer Nature, 2016-03-21) Kanellopoulos, A.; Saeed, M.; Eden, D.; Qureshi, I.; Cain, L.; Khawaja, J.; Kaparou, M.; Xenou, E.; Borg, A.; Arbuthnot, C.; Randall, K.; Lee, S.; Holder, K.; Bratby, L.; Kishore, B.; Lovell, R.; Paneesha, S.; Nikolousis, E.; Heart of England NHS Trust; South Warwickshire University NHS Foundation Trust; New Cross Hospital, Wolverhampton; Haematology; Medical and Dental; Borg, A.; Arbuthnot, C.; Randall, K.
    Physicians Poster Sessions abstract P246 of the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, Valencia, Spain, 3–6 April 2016.
  • Publication
    Severe cytomegalovirus reactivation in patient with low-grade non-Hodgkin’s lymphoma after standard chemotherapy
    (Wiley, 2017-10-22) Modvig, Lena; Boyle, Ciaran; Randall, Katie; Borg, Anton; South Warwickshire University NHS Foundation Trust; Haematology; Medical and Dental; Modvig, Lena; Boyle, Ciaran; Randall, Katie; Borg, Anton
    Clinically significant cytomegalovirus (CMV) reactivation is not uncommon in patients with severe immunodeficiency secondary to underlying medical disorders or following aggressive immunosuppressive therapy. However, it is less frequently found in patients with low-grade haematological malignancies after nonintensive chemotherapy. We treated a patient at our centre for stage IVB follicular lymphoma with standard chemotherapy who successively developed CMV colitis associated with a CMV viral load of >3 million copies/ml. Four lines of antiviral treatment were necessary to obtain biochemical remission with undetectable CMV levels, with an initially insufficient response to valganciclovir despite therapeutic pre- and posttreatment levels. Subsequently, our patient also developed an infection with Pneumocystis jirovecii pneumonia (PJP) as further evidence of severe immune compromise. This case report demonstrates the importance of including investigations for less common sources of infection when confronted with a patient with a low-grade haematological malignancy and a pyrexia of unknown origin.
  • Publication
    Clinical and treatment‐related features determining the risk of late relapse in patients with diffuse large B‐cell lymphoma
    (Wiley, 2017-06-27) Modvig, Lena; Vase, Maja; d‘Amore, Francesco; University Hospital of Aarhus, Aarhus, Denmark; Warwick Hospital; Department of Haematology; Medical and Dental; Modvig, Lena
    It is still unclear whether there are clinically exploitable differences in the biology and behaviour of early versus late relapses in diffuse large B-cell lymphoma (DLBCL). The present study aimed to analyse a large population-based DLBCL cohort in order to identify (i) the frequency of late relapses (LR), (ii) parameters influencing the risk of LR, and (iii) the impact of introducing rituximab on the occurrence of LR. The data of 7247 DLBCL patients was obtained from the Danish Lymphoma Group Registry. Patients with LR had a lower International Prognostic Index and better performance score than early relapse (ER) patients. The use of radiotherapy lowered only the rate of ER while the use of rituximab yielded a lower occurrence of both ER and LR (P < 0·0001 and P < 0·0001, respectively), possibly suggesting a longer-lasting biological effect. Additionally, we found a female overrepresentation among LR patients that had received a rituximab-containing first line treatment. It was found that patients with LR had a significantly better 5-year overall survival compared to ER patients. In conclusion, LR was more frequently associated with low-risk features than ER. Furthermore, we found that the use of modern immunochemotherapy regimens in DLBCL lowers the risk of both ER and LR.
  • Publication
    A double centre retrospective study into rates of postpartum haemorrhage in women on low molecular weight heparin
    (Wiley, 2016-02-05) Arbuthnot, Carolina; Browne, Rachael; Nicole, Sarah; Erb, Sarah J.; Farrall, Louise; Borg, Anton; University Hospitals Coventry and Warwickshire NHS Trust; South Warwickshire University NHS Foundation Trust; Department of Haematology; Medical and Dental; Arbuthnot, Carolina; Borg, Anton
    An investigation into the rates of PPH in women prescribed LMWH antenatally at two local hospitals.
  • Publication
    Three-month mixed T-cell chimerism followed by donor lymphocyte infusions is associated with superior outcomes in reduced-intensity alemtuzumab based allogeneic stem cell transplants for haematological malignancies
    (Springer Nature, 2018-11-19) Kanellopoulos, Alexandros; McIlroy, Graham; Paneesha, Shankara; Kaparou, Maria; Kishore, Bhuvan; Lovell, Richard; Elmoamly, Shereef; Davies, David; Xenou, Evgenia; Horgan, Claire; Kinsella, Francesca; Arbuthnot, Carolina; Borg, Anton; Randall, Katie; Ryann, Lynn; Collins, Katie; Holder, Kathleen; Pryor, Rebecca; Gudger, Amy; Giles, Hannah; Milligan, Donald; Nikolousis, Emmanouil; Heart of England NHS Foundation Trust; University of Birmingham; South Warwickshire University NHS Foundation Trust; Haematology; Aylesford Unit; Medical and Dental; Arbuthnot, Carolina; Borg, Anton; Randall, Katie
    This European Society for Blood and Marrow Transplantation conference abstract reports that three-month mixed T-cell chimerism followed by donor lymphocyte infusions is associated with superior outcomes in reduced-intensity alemtuzumab based allogeneic stem cell transplants for haematological malignancies.
  • Publication
    COVID-19 in haematology patients : a multicentre West Midlands clinical outcomes analysis on behalf of the West Midlands Research Consortium
    (Wiley, 2020-11-05) Morrissey, Hana; Ball, Patrick; Mandal, Anandadeep; Nevil, Alan; Paneesha, Shankara; Basu, Supratik; Karim, Farheen; Hossain, Md Imran; Phillips, Neil; Khawaja, Jahanzeb; Stone, Jackie; Murray, Duncan; Randall, Katie; Murthy, Vidhya; Kishore, Bhuvan; Nikolousis, Manos; Pratt, Guy; Neilson, Jeff; Pemberton, Nick; Wandroo, Farooq; University of Wolverhampton; University of Birmingham; University Hospitals Birmingham NHS Trust; Royal Wolverhampton NHS Trust; Royal Blackburn Teaching Hospital; University Hospitals of North Midlands NHS Trust; University Hospitals Coventry and Warwickshire NHS Trust; South Warwickshire NHS Foundation Trust; Dudley Group NHS Foundation Trust; Worcestershire Acute Hospitals NHS Trust; Sandwell and West Birmingham Hospitals NHS Trust; Haematology; General Medicine; Medical and Dental; Randall, Katie; Paneesha, Shankara; Murthy, Vidhya; Kishore, Bhuvan; Nikolousis, Manos
    A retrospective study analysing clinical outcomes of adult patients with both an underlying haematological disorder and confirmed COVID-19.
  • Publication
    Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
    (Wiley, 2023-06-12) Loke, Justin; Upasani, Vinit; Gaskell, Charlotte; Fox, Sonia; Fletcher, Rachel; Thomas, Catherine; Hopkins, Louise; Kumari, Anita; Tang, Tina; Yafai, Emily; Boucher, Rebecca; Homer, Victoria; Toth, Arpad; Chan, Y L Tracey; Randall, Katie; Rider, Tom; O'Nions, Jenny; Drew, Victoria; Pillai, Arvind; Dungarwalla, Moez; Murray, Duncan; Khan, Anjum; Wandroo, Farooq; Moore, Sally; Krishnamurthy, Pramila; Huang, Ya-Wen Jessica; Knapper, Steve; Byrne, Jenny; Zhao, Rui; Craddock, Charles; Parry, Helen; Moss, Paul; Stanworth, Simon J; Lowe, David M; Murray, Duncan; Medicine; Medical and Dental; Murray, Duncan
    Limited data exist on COVID-19 vaccination efficacy in patients with acute myeloid leukemia and myelodysplasia with excess blasts (AML/MDS-EB2). We report results from a prospective study, PACE (Patients with AML and COVID-19 Epidemiology). 93 patients provided samples post-vaccine 2 or 3 (PV2, PV3). Antibodies against SARS-COV-2 spike antigen were detectable in all samples. Neutralization of the omicron variant was poorer than ancestral variants but improved PV3. In contrast, adequate T-cell reactivity to SARS-COV-2 spike protein was seen in only 16/47 (34%) patients PV2 and 23/52 (44%) PV3. Using regression models, disease response (not in CR/Cri), and increasing age predicted poor T cell response.
  • Publication
    Non-Hodgkin lymphoma causing hypopituitarism - can imaging help diagnosis and management?
    (SMC media, 2021-12) Khan, Uzma; Borg, Anton; Beltechi, Radu; Mehta, Hiten; Robbins, Timothy; Randeva, Harpal; Machenahalli, Pratibha; University Hospitals Coventry & Warwickshire NHS Trust; South Warwickshire University NHS Foundation Trust; Haematology; Trauma and Neuro Services; Clinical Diagnostic Services; Medicine; Medical and Dental; Borg, Anton; Khan, Uzma; Beltechi, Radu; Mehta, Hiten
    Non-Hodgkin lymphomas of the hypothalamus and pituitary are rare. They usually remain clinically silent until onset of compressive features affecting surrounding structures. When symptomatic, patients most commonly present with diabetes insipidus, headaches, ophthalmoplegia and/or bilateral hemianopia. We report a case of a 67-year-old Caucasian female with a history of B-cell lymphoma in complete remission. She presented with left oculomotor nerve palsy and was subsequently found to have a sellar/suprasellar mass lesion on MRI. Alongside hypocortisolism and hypogonadotropic hypogonadism, she developed transient diabetes insipidus during her illness. Her clinical course was characterized by rapid intracranial progression of the sellar mass. MR spectroscopy suggested a diagnosis of lymphoma. Diagnostic biopsy confirmed high-grade diffuse large B-cell CNS lymphoma; this changed the definitive management from surgical excision to chemotherapy. Despite treatment, she succumbed to her illness within 7 months of initial presentation. This case highlights the aggressive nature of CNS lymphomas and the need for a high index of suspicion in an unusual presentation of sellar/suprasellar mass lesions. Learning points: Novel imaging techniques such as MR spectroscopy might help to differentiate some brain tumours from pituitary macroadenomas, but these are not diagnostic.Tissue diagnosis with biopsy and histopathology is the gold standard for deciding management of pituitary fossa mass lesions with atypical presentation.